MBS Rebate for Liver Fibrosis Testing in 2026 | Elastography Australia
Australian clinicians: what MBS item 55292 covers for liver fibrosis, who can claim, and how to integrate elastography into your MBS billing.
If you're considering adding liver elastography to your practice, one of the first questions your practice manager will ask is: does it attract a Medicare rebate?
The short answer: yes, under specific conditions. The longer answer requires understanding how MBS item 55292 works, which providers can claim it, and what clinical documentation you'll need.
This article gives you a practical overview. Always verify current descriptors and fees with Services Australia or your billing advisor before claiming, as MBS schedules are updated periodically.
MBS Item 55292 — The Basics
MBS item 55292 covers transient elastography of the liver. The item is available for eligible patients with suspected or confirmed liver fibrosis, subject to clinical indication criteria set out in the item descriptor.
The commonly cited schedule fee for 55292 has historically ranged in the vicinity of $90–$120 (verify the current fee on the MBS Online schedule at mbsonline.gov.au). This fee applies to the professional service — equipment, facility, and interpretation costs are separate considerations for your practice economics.
Who Can Claim?
Item 55292 can be claimed by eligible providers in appropriate clinical settings. The key distinctions are:
• General practitioners: can claim in certain circumstances, particularly where the GP is performing the scan and the clinical indication is documented.
• Specialists (gastroenterologists, hepatologists): standard claim pathway in specialist consulting rooms.
• Imaging centres: claiming under diagnostic imaging provider rules — check whether your device type and workflow meet the item descriptor expectations.
Provider type, clinical setting, and patient eligibility all interact. If you're setting up a new elastography service, confirm your specific circumstances with your peak body or billing advisor before your first claim.
What Clinical Documentation Is Required?
To support an MBS claim for 55292, your clinical record should demonstrate:
• A documented clinical indication — typically suspected liver fibrosis or established chronic liver disease requiring staging.
• The reason elastography was chosen over, or in addition to, blood-based fibrosis markers.
• Relevant history: diagnosis of MAFLD, hepatitis B or C, alcohol-related liver disease, or other relevant chronic liver condition.
• Any prior FIB-4 or APRI result that prompted further assessment.
• The scan result in kPa and interpretation against recognised thresholds (e.g., <7 kPa normal, 7–9.5 kPa indeterminate for MAFLD, >9.5 kPa suggests significant fibrosis).
Incomplete documentation is the most common reason for MBS audit risk. A simple clinical note template — built into your practice management software — can make compliance straightforward.
Frequency Limits and Co-Claiming
Item 55292 has co-claiming restrictions with certain other items and frequency limits on repeat claims. Before setting up automated recall or monitoring protocols, confirm the current frequency rules with Services Australia. Rules have changed before and may change again as the MSAC evaluates the evidence base for elastography in primary care.
The ROI Question Beyond MBS
Even where MBS does apply, many practices charge a gap or operate on a private basis. The device economics still work — particularly for imaging centres and GP practices serving high-volume chronic disease populations.
A practice running 15 scans per week at $150 per scan generates approximately $9,000 in monthly revenue. With a guided elastography system supplied through Elastography Australia at approximately half the cost of traditional systems, payback periods of 5–8 months are achievable on these volumes.
Monitoring Changes — Staying Current
MBS policy for non-invasive liver disease testing is an active area. The Medical Services Advisory Committee (MSAC) has been evaluating evidence for liver elastography in primary care, and further changes to item descriptors, schedule fees, or provider eligibility are possible in 2026 and beyond.